摘要
The extent of heterogeneity in a meta-analysis partly determines the difficulty in drawing overall conclusions. This extent may be measured by estimating a between-study variance, but interpretation is then specific to a particular treatment effect metric. A test for the existence of heterogeneity exists, but depends on the number of studies in the meta-analysis. We develop measures of the impact of heterogeneity on a meta-analysis, from mathematical criteria, that are independent of the number of studies and the treatment effect metric. We derive and propose three suitable statistics: H is the square root of the chi(2) heterogeneity statistic divided by its degrees of freedom; R is the ratio of the standard error of the underlying mean from a random effects meta-analysis to the standard error of a fixed effect meta-analytic estimate, and I-2 is a transformation of H that describes the proportion of total variation in study estimates that is due to heterogeneity. We discuss interpretation, interval estimates and other properties of these measures and examine them in five example data sets showing different amounts of heterogeneity. We conclude that H and I-2, which can usually be calculated for published meta-analyses, are particularly useful summaries of the impact of heterogeneity. One or both should be presented in published meta-analyses in preference to the test for heterogeneity.
学科与关键词
- Effect of acupoint catgut embedding in chronic fatigue syndrome patientsMei-Lin, Zhang; Hong-Juan, Fu; Yong, Tang; Zhen-Guo, Luo; Jian-Yong, Li; Rui, LiMedicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2021, 100(5): e23946.
- Diagnostic accuracy, yield, and comparative effectiveness of whole-body computed tomography in blunt traumaKyohei, Nagasawa; Mitsunaga, Iwata; Takashi, Nihashi; Teruhiko, TerasawaMedicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2021, 100(2): e24205.
- Hepatotoxicity with epidermal growth factor receptor tyrosine kinase inhibitors in non–small‐cell lung cancer patients: A network meta‐analysisZiyang, Wu; Suhua, Chen; Xin, Du; Yibo, Wu; Xiaohui, XieJournal of Clinical Pharmacy and Therapeutics, 2021, 46(2): 310-318.
